U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07625124) titled 'A Phase 2 Study of RCI001 Ophthalmic Solution in Participants With Dry Eye Disease' on May 12.
Brief Summary: This is a Phase 2 clinical study designed to evaluate the safety and efficacy of 0.25% RCI001 Ophthalmic Solution compared with placebo in participants with dry eye disease.
The study will enroll adults with dry eye disease. After a 2-week run-in period with placebo ophthalmic solution, eligible participants will be randomly assigned to receive either 0.25% RCI001 Ophthalmic Solution or placebo ophthalmic solution in both eyes for 4 weeks. Study treatment will be administered either twice daily or four times daily, depending...